President, Sohn Health Strategies
DR. CATHERINE ANGELL SOHN, Pharm.D., President, Sohn Health Strategies, LLC is an independent director on the Boards of Jazz Pharmaceuticals (NASDAQ: JAZZ), Landec Corp (NASDAQ: LNDC), Neuralstem, Inc. (NYSEMKT: CUR), CHD Bioscience (privately held) and Dohmen Life Science Services (privately held). Dr. Sohn was formerly senior vice president of business development and strategic alliances at GlaxoSmithKline Consumer Healthcare (1998-2010). Earlier during her 28-year tenure at GlaxoSmithKline, Dr. Sohn was vice president for worldwide strategic product development for the cardiovascular, pulmonary and metabolic therapeutic areas, with responsibility for product strategy, valuation, and strategic commercial leadership of assets from phase 1 through global life cycle management.
Dr. Sohn concurrently serves as Dean’s Professor (adjunct) at the University of the Sciences in Philadelphia and is a member of the board of the World Affairs Council of Philadelphia, the Dean’s Advisory Council for Drexel University School of Public Health, the Advisory Board of Drexel’s Center for Corporate Governance, the External Advisory Board for Drexel University Close School of Entrepreneurship, the Ben Franklin Technology Partners Life Science Investment Advisory Committee, Springboard Enterprises Life Science Council, and formerly, was a member of the Johns Hopkins Bloomberg School of Public Health Advisory Board and the UCSF School of Pharmacy, Board of Overseers.
A native of California, Dr. Sohn received a Doctor of Pharmacy degree from the University of California San Francisco, a Certificate of Professional Development from the Wharton School at the University of Pennsylvania, is an NACD Governance Fellow and is a Certified Licensing Professional. She and her husband, Dr. John Sohn have two daughters.